Emerging innovations in clinical trial design

Clinical Pharmacology and Therapeutics

Volumn 99, Issue 1, 2016, Pages 82-91

  Berry, D A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER RESEARCH; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DOSE CALCULATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; ONCOLOGY; PRIORITY JOURNAL; METHODOLOGY; PROCEDURES;

CLINICAL TRIALS AS TOPIC; HUMANS; MEDICAL ONCOLOGY; RESEARCH DESIGN;

EID: 84955270265     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.285     Document Type: Article

References (44)

1. Office of the Secretary, United States Department of Health, Education and Welfare, (18 April 1979) Federal Register 44 (76): 23191-7. Part A. Boundaries Between Practice and Research. < http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.html >. Accessed 16 August 2015.
2. Oncology Times. 35, 11-12 (2013). DOI: 10.1097/01.COT.0000432325.77902.74.
3. Berry, D.A., Adaptive clinical trials in oncology. Nat. Rev. Clin. Oncol. 9, 199-207 (2012).
4. Berry, D.A., The Brave New World of clinical cancer research: adaptive biomarker-driven trials integrating clinical practice with clinical research. Mol. Oncol. 9, 951-959 (2015).
5. Berry, D.A., A case for Bayesianism in clinical trials (with discussion). Statistics in Medicine 12, 1377-1404 (1993).
6. Berry, D.A., Bayesian statistics and the efficiency and ethics of clinical trials. Statistical Science 19, 175-187 (2004).
7. Berry, D.A., A guide to drug discovery: Bayesian clinical trials. Nat. Rev. Drug Discov. 5, 27-36 (2006).
8. Berry, D.A., Statistics: A Bayesian Perspective (Duxbury Press, Belmont, CA, 1996).
9. Biswas, S., Liu, D.D., Lee, J.J., &, Berry, D.A., Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. Clin. Trials 6, 205-216 (2009).
10. Berry, D.A., &, Eick, S.G., Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. Stat. Med. 14, 231-246 (1995).
11. < https://clinicaltrials.gov/ct2/show/NCT02465060 >. Accessed 16 August 2015.
12. < http://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match >. Accessed 16 August 2015.
13. Simon, R., Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials 10, 1-10 (1989).
14. Prahallad, A., et al,. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103 (2012).
15. Helwick, C., BRAF mutations in colorectal cancer: the next frontier. ASCO Post 4. < http://www.ascopost.com/issues/april-15,-2013/braf-mutations-in-colorectal-cancer-the-next-frontier.aspx >. (2013). Accessed 16 August 2015.
16. Kang, B.P., et al,. The Signature program: bringing the protocol to the patient. Clin. Pharmacol. Ther. 98, 124-126 (2015).
17. Stein C,. Inadmissibility of the usual estimator for the mean of a multivariate normal distribution. Proc. Third Berkeley Symp. Math. Stat. Prob. Vol 1 197-206 (University of California Press, Berkeley, CA, 1956).
18. Efron, B., &, Morris, C., Stein's paradox in statistics. Sci. Am. 5, 119-127 (1977).
19. James, W., &, Stein, C., Estimation with quadratic loss. Proc. Fourth Berkeley Symp. Math. Stat. Prob. Vol 1 361-379, (University of California Press, Berkeley, CA).
20. Berry, S.M., Carlin, B.P., Lee, J.J., &, Muller, P., Bayesian Adaptive Methods for Clinical Trials (Chapman and Hall/CRC Press, Boca Raton, FL, 2010).
21. Lung-MAP. A groundbreaking collaborative approach to clinical trials. < http://www.lung-map.org >. Accessed 16 August 2015.
22. Lung-MAP. S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer. < https://clinicaltrials.gov/ct2/show/NCT02154490 >. Accessed 16 August 2015.
23. < www.ispy2.org >. Accessed 16 August 2015.
24. < https://clinicaltrials.gov/ct2/show/NCT01042379 >. Accessed 16 August 2015.
25. Barker, A.D., et al,. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Ther. 86, 97-100 (2009).
26. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an end point to support accelerated approval. October 2014. < http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm305501.pdf >. Accessed 16 August 2015.
27. SABCS 2013;, Rugo, H.S., et al,. Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: first efficacy results from the I-SPY 2 trial. 2013 San Antonio Breast Cancer Symposium. Abstract S5-02. Presented December 13, 2013.
28. AACR2014; < http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3404&sKey=ed5341ec-ef13-493e-8844-e14be322679c&cKey=d9b44ad7-1673-4ec9-b360-11254fbb92be&mKey=6ffe1446-a164-476a-92e7-c26446874d93 >. Accessed 16 August 2015.
29. ASCO 2015. < http://meetinglibrary.asco.org/content/150770-156 >. Accessed 16 August 2015.
30. < http://www.imi.europa.eu >. Accessed 16 August 2015.
31. Goldman, M., Seigneuret, N., &, Eichler, H.-G., The Innovative Medicines Initiative: an engine for regulatory science. Nat. Rev. Drug Discov. 14, 1-2 (2015).
32. Collins, S.P., et al,. Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial. Am. Heart J. 164, 138-145.
33. < http://www.PREPARE-Europe.eu/About-us/Partners >. (2012) Accessed 16 August 2015.
34. Berry, D.A., et al,. Adaptive Bayesian designs for dose-ranging drug trials. In Case Studies in Bayesian Statistics V (ed., Gatsonis, C., et al.) 99-181 (Springer, New York, 2001).
35. Skrivanek, Z., et al,. Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): statistical design and simulations. J. Diabetes Sci. Technol. 6, 1305-1318 (2012).
36. Geiger, M.J., Skrivanek, Z., Gaydos, B., Chien, J., Berry, S., Berry, D., Anderson, J.H,. An adaptive, dose-finding, seamless phase 2/3 study of a long-acting glucagon-like peptide-1 analog (dulaglutide): trial design and baseline characteristics. J. Diabetes Sci. Technol. 6, 1319-1327 (2012).
37. " Guidance for Industry, Adaptive Design Clinical Trials for Drugs and Biologics " Draft February 2010 < http://www.fda.gov/downloads/Drugs/./Guidances/ucm201790.pdf >. Accessed 16 August 2015.
38. < http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm415180.htm >. Accessed 16 August 2015.
39. < http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002825/WC500179473.pdf >. Accessed 16 August 2015.
40. Anscombe, F.J., Sequential medical trials. J. Am. Stat. Assoc. 58, 365-383 (1963).
41. Colton, T., A model for selecting one of two medical treatments. J. Am. Stat. Assoc. 58, 388-400 (1963).
42. Cheng, Y., Su, F., &, Berry, D.A., Choosing sample size for a clinical trial using decision analysis. Biometrika 90, 923-936 (2003).
43. Berry, D.A., Modified two-armed bandit strategies for certain clinical trials. J. Am. Stat. Assoc. 73, 339-345 (1978).
44. Witmer, J.A., Bayesian multistage decision problems. Ann. Stat. 14, 283-297 (1986).